Skip to main content
AmigoFish

STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class

From BiotechTV - News · · 11 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

He describes the profile of the company's orexin and its development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like ADHD, MS, and Parkinson's further on down the line. Plus how the acquisition of Avadel has been a fit, and whether he would consider doing additional deals.

Back to BiotechTV - News · Report a problem